汇宇制药：HYP-6589片联合用药获得药物临床试验批准通知书

Core Viewpoint - Huyou Pharmaceutical's subsidiary has received approval for a clinical trial of a new drug aimed at treating advanced non-small cell lung cancer in combination with Osimertinib [1] Group 1: Company Developments - Huyou Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huyou Haiyue Pharmaceutical Technology Co., Ltd., has received the Clinical Trial Approval Notice from the National Medical Products Administration [1] - The new chemical entity, HYP-6589 tablets (development code "HY-0006"), is intended for use in clinical trials for treating advanced non-small cell lung cancer with target-driven gene positivity in combination with Osimertinib [1] Group 2: Industry Context - The approval of HYP-6589 for clinical trials highlights the ongoing innovation in the oncology sector, particularly in targeted therapies for lung cancer [1] - The combination therapy approach reflects a growing trend in the pharmaceutical industry to enhance treatment efficacy for specific patient populations [1]